Endometrial cancer trial XPORT-EC-042
Автор: ANZGOG
Загружено: 2024-04-22
Просмотров: 75
The XPORT-EC-042 study is led by Karyopharm Therapeutics (Global Sponsor), in collaboration with ANZGOG, European Network of Gynaecological Oncological Trial Groups (ENGOG) and GOG Foundation.
XPORT-EC-042 is led by Coordinating Principal Investigators A/Prof Yoland Antill and Dr. Kate Webber in ANZ, and aims to respond to the growing complexity of managing endometrial cancer, the XPORT-EC-042 trial aims to evaluate the benefit of selinexor in patients with no P53 alteration in advanced or recurrent endometrial cancer. Patients will receive either oral selinexor or placebo as maintenance therapy following chemotherapy, until disease progression.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке: